The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal antibodies, there has been no benefit of mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Turalde-Mapili, Maria Wilma R., Mapili, Jerahmeel Aleson L., Turalde, Christian Wilson R., Pagcatipunan, Marimel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110918/
https://www.ncbi.nlm.nih.gov/pubmed/37082704
http://dx.doi.org/10.3389/fped.2023.1132740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110918/
https://www.ncbi.nlm.nih.gov/pubmed/37082704
http://dx.doi.org/10.3389/fped.2023.1132740

Ejemplares similares